Benchmarking outcomes of endoscopic retrograde cholangio-pancreatography for malignant biliary obstructions: A multicenter real-world study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cecilia Binda, Alessandro Cucchetti, Andrea Anderloni, Giorgio Arcidiacono Paolo, Roberto Di Mitri, Francesco Crinò Stefano, Romano Sassatelli, Enrico Piras, Alessandro Mussetto, Alessandro Fugazza, Chiara Coluccio, Lorenzo Fuccio, Luigi Cugia, Marco Di Marco, Maria Di Matteo Francesco, Vincenzo Cennamo, Cristiano Spada, Mauro Manno, Arnaldo Amato, Alberto Fantin, Massimiliano Mutignani, Marta Stegagnini, Giovanni Aragona, Claudio De Angelis, Gianmarco Marocchi, Alberto Merighi, Raffaele Macchiarelli, Giuseppe Vanella, Michele Amata, Armando Gabbrielli, Vincenzo Mirante, Alessandro Repici, Ilaria Tarantino, Carlo Fabbri, i-EUS Group
Аннотация
AIMS: This study aimed to determine risk-adjusted outcomes following ERCP for malignant biliary obstruction(MBO).
METHODS: Using an intention-to-treat approach, we analyzed data from a multicenter database including 23 Italian hospitals (2017-2022). Inter-center heterogeneity was assessed with I² statistic. To account for case-mix confounding, multivariable mixed-effects models estimated risk-adjusted outcomes.
RESULTS: Clinical and procedural characteristics showed considerable heterogeneity across centers (I²>75%). In the intention-to-treat cohort (n = 3148), the risk-adjusted technical success rate was 91.3%; the intraclass correlation coefficient (ICC) was 11.6%, suggesting that 11.6% of the outcome variance resides at the hospital level. In the per-successful-procedure cohort (n = 2665), the risk-adjusted technical success rate was 91.3% (ICC 22.7%). Post-ERCP pancreatitis occurred in 5.4% (ICC 12.9%), additional ERCPs were required in 23.7% (ICC 4.1%), and 30-day mortality was 4.2%. Treatment in high-volume hospitals (>350ERCPs/year) was associated with lower mortality(p = 0.001).
CONCLUSIONS: Most variability in ERCP outcomes across hospitals reflects differences in patient selection and technical strategies. After risk adjustment, outcomes were similar across centers, supporting consistent quality of care. This study provides exploratory, risk-adjusted benchmarks derived from real-world practice for ERCP in MBO and supports their use for quality monitoring and referral planning.